NewAmsterdam Pharma N.V. (NAMS) News
NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NAMS news summary
We found 3 recent headlines mentioning NewAmsterdam Pharma N.V. (NAMS): 0 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. NAMS is making an outsized move today, down 5.64% at $18.41, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", was published by GlobeNewswire on Nov 6, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest NewAmsterdam Pharma N.V. headlines
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NAARDEN, the Netherlands and MIAMI, Nov. 06, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical…GlobeNewswire
- NewAmsterdam Pharma Company N.V. Reports Third Quarter Financial Results and European Commission ApprovalNewAmsterdam Pharma Company N.V. reported its financial results for the quarter ended September 30, 2026, recognizing revenue of $19.2 million, compared to $0.3 million in the same period in 2025.…Nasdaq
- NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results– Received European Commission approval for Ubeslo® (obicetrapib monotherapy) and Evlarco® (obicetrapib plus ezetimibe fixed-dose combination), marking the first regulatory approval of obicetrapib…GlobeNewswire